Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines

Nuclear Medicine and Biology

Volumn 35, Issue 3, 2008, Pages 273-279

  Vavere, Amy L ^a   Lewis, Jason S ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

Cu ATSM; Fatty acid synthase; PET; Prostate cancer

Indexed keywords

C 75; COPPER 64; DIACETYL BIS(N 4 METHYLTHIOSEMICARBAZONE); FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; TRACER; UNCLASSIFIED DRUG;

ANOXIA; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; HYPOXIA; ISOTOPE LABELING; PROSTATE CANCER; PROTEIN EXPRESSION;

4-BUTYROLACTONE; CELL HYPOXIA; CELL LINE, TUMOR; COPPER RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FATTY ACID SYNTHETASE COMPLEX; GENE EXPRESSION; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; THIOSEMICARBAZONES;

EID: 40749099450     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.11.012     Document Type: Article

References (55)

1. Brown J.M. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 59 (1999) 5863-5870
2. Tatum J.L., Kelloff G.J., Gillies R.J., Arbeit J.M., Brown J.M., Chao K.S.C., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82 (2006) 699-757
3. Höckel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 (2001) 266-276
4. Crabtree H.G., and Cramer W. The action of radium on cancer cells I, II. Some factors determining the susceptibility of cancer cells to radium. Proc Royal Soc Biol Sci 113 (1933) 238-250
5. Gray L.H., Conger A.D., Ebert M., Hornsey S., and Scott O.C. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 (1953) 638-648
6. Tannock I., and Guttman P. Responses of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer 42 (1981) 245-248
7. Teicher B.A., Holden S.A., Al-Achi S.A., and Herman T.S. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50 (1990) 3339-3344
8. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
9. Gatenby R.A., Kessler H.B., Rosenblum J.S., Coia L.R., Moldofsky P.J., Hartz W.H., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14 (1988) 831-838
10. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
11. Rajendran J.G., and Krohn K.A. Imaging hypoxia and angiogenesis in tumors. Radiologic Clin N Am 43 (2005) 169-187
12. Nunn A., Linder K., and Strauss H.W. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 22 (1995) 265-280
13. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10 (2004) 2245-2252
14. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30 (2003) 695-704
15. 18F-FDG PET. J Nucl Med 47 (2006) 1921-1926
16. 18F-fluoroazomycin arabinoside. J Nucl Med 46 (2005) 106-113
17. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 30 (2003) 317-326
18. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 34 (2007) 1566-1575
19. Vavere A.L., and Lewis J.S. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 43 (2007) 4893-4902
20. Dearling J.L.D., Lewis J.S., Mullen G.E.D., Rae M.T., Zweit J., and Blower P.J. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 25 (1998) 788-792
21. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., and Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38 (1997) 1155-1160
22. 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55 (2003) 1233-1238
23. 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30 (2003) 844-850
24. 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum (2008) [in press]
25. 60Cu-ATSM. J Nucl Med 49 (2008) 201-205
26. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 40 (1999) 177-183
27. Burgman P., O'Donoghue J.A., Lewis J.S., Welch M.J., Humm J.L., and Ling C.C. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 32 (2005) 623-630
28. 2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61 (2005) 1493-1502
29. 11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 49 (2008) 327-334
30. Wakil S.J. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28 (1989) 4523-4530
31. Myers R.B., Oelschlager D.K., Weiss H.L., Frost A.R., and Grizzle W.E. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol 165 (2001) 1027-1032
32. Hochachka P.W., Rupert J.L., Goldenberg L., Gleave M., and Kozlowski P. Going malignant: the hypoxia-cancer connection in the prostate. BioEssays 24 (2002) 749-757
33. 64Cu using a biomedical cyclotron. Nucl Med Biol 24 (1997) 35-43
34. Gillemin K., and Krasnow M.A. The hypoxic response: huffing and HIFing. Cell Death Differ 89 (1997) 9-12
35. 2 tension. Am J Physiol 271 (1996) C1172-C1180
36. Höckel M., Schlenger K., Aral B., Mitze M., Shäffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advancer cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
37. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond) 379 (1996) 88-91
38. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond) 359 (1992) 843-845
39. Chao C., Bosch W.R., Mutic S., Lewis J.S., Dehdashti F.D., Mintun M.A., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
40. 4-methylthiosemicarbazone). J Nucl Med 47 (2006) 989-998
41. Dearling J.L.J., Lewis J.S., Mullen G.E.D., Welch M.J., and Blower P.J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 7 (2002) 249-259
42. Maurer R.I., Blower P.J., Dilworth J.R., Reynolds C.A., Zheng Y., and Mullen G.E.D. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 45 (2002) 1420-1431
43. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30 (2003) 607-611
44. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Sooryanarayana V., Kurachi K., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
45. Swinnen J.V., Roskams T., Joniau S., Van H., Poppel R., Oyen L., et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98 (2002) 19-22
46. Welsh J.B., Sapinosa L.M., Su A.I., Kern S.G., Wang-Rodriguez J., Moskaluk C.A., et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61 (2001) 5974-5978
47. Menendez J.A., and Lupu R. Oncologic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care 9 (2006) 346-357
48. Alo P.L., Visca P., Trombetta G., Mangoni A., Lenti L., Monaco S., et al. Fatty acid synthase (FAS) predictive strength in poly differentiated early breast carcinomas. Tumori 85 (1999) 35-40
49. Alo P.L., Visca P., Marci A., Mangoni A., Botti C., and Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77 (1996) 474-482
50. Gansler T.S., Hardman W., HD A., Schaffel S., and Hennigar R.A. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Human Pathol 28 (1997) 686-692
51. Rashid A., Pizer E.S., Moga M., Milgraum L.Z., Zahurak M., Pasternack G.R., et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150 (1997) 201-208
52. Wang Y., Kuhajda F.P., Li J.N., Pizer E.S., Han W.F., Sokoll L.J., et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett 167 (2001) 99-104
53. Rossi S., Graner E., Febbo P., Weinstein L., Bhattacharya N., Onody T., et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1 (2003) 707-715
54. Takahiro T., Shinichi K., and Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 9 (2003) 2204-2212
55. Loftus T.M., Jaworsky D.E., Frehywot G.L., Townsend C.A., Ronnett G.V., Lane M.D., et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288 (2000) 2379-2381